-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: The all-oral hepatitis C treatment is composed of Ravidawe (Shinlilai) in conjunction with Danoriv (Gonovi).
Co., Ltd. announced today that its all-oral hepatitis C treatment program has been approved for listing by the State Drug Administration of China.
's all-oral hepatitis C treatment (RDV/DNV treatment) is made up of Ravidawe (Xinlilai) in conjunction with Danorive (Gonove).
The results of Phase II/III clinical trials completed in China showed that, after 12 weeks of treatment, the RDV/DNV treatment regimen had a cure rate of 99% in patients with gene type 1 non-cirrhosis (SVR12), and 100% of patients with NS5A drug resistance mutations at baseline shaded.
Ravidawe and Danoriwe have been supported by the national 13th Five-Year New Drug Creation science and technology projects.
2014, Clarisse acquired an exclusive interest in Ravidawe in Greater China from Presidio.
Presidio is a clinical pharmaceutical company.
.